Recent Advances in Progresses and Prospects of IL-37 in Central Nervous System Diseases.
作者信息
Li Xinrui, Yan Bing, Du Jin, Xu Shanshan, Liu Lu, Pan Caifei, Kang Xianhui, Zhu Shengmei
机构信息
Department of Anesthesiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Department of Anesthesiology, Haining People's Hospital, Haining 314499, China.
出版信息
Brain Sci. 2022 May 31;12(6):723. doi: 10.3390/brainsci12060723.
Interleukin-37 (IL-37) is an effective anti-inflammatory factor and acts through intracellular and extracellular pathways, inhibiting the effects of other inflammatory cytokines, such as IL-1β, IL-6, and tumor necrosis factor-α (TNF-α), thereby exerting powerful anti-inflammatory effects. In numerous recent studies, the anti-inflammatory effects of IL-37 have been described in many autoimmune diseases, colitis, and tumors. However, the current research on IL-37 in the field of the central nervous system (CNS) is not only less, but mainly for clinical research and little discussion of the mechanism. In this review, the role of IL-37 and its associated inflammatory factors in common CNS diseases are summarized, and their therapeutic potential in CNS diseases identified.